A former college athlete spent years hiding a depression so severe that it once took several people to lift him off his couch and carry him out the door.
Quick Take
- Jeremiah, a former college athlete, was diagnosed with major depressive disorder in 2012 after symptoms started in college and worsened after graduation.
- He tried multiple antidepressants over the years without lasting relief, a pattern doctors call treatment-resistant depression.
- His doctor eventually recommended SPRAVATO, an esketamine nasal spray approved for hard-to-treat depression.
- His wife and doctor played key roles in his recovery alongside the medication.
- Research on esketamine shows real benefits for many patients, though results vary from person to person.
A Breaking Point That Took Years To Build
Jeremiah’s story, first reported by Men’s Health, started quietly in college. Teammates and coaches saw a strong athlete. Few saw the sadness building underneath. After graduation, the symptoms got worse. Life without the structure of a team and a season schedule seemed to strip away the routines that had been holding him together.
By 2012, doctors gave his struggle a name: major depressive disorder. A diagnosis can bring relief for some people. For Jeremiah, it marked the start of a much longer fight. He began the slow, frustrating process familiar to many depression patients, trying medication after medication, hoping one would finally work.
When Standard Treatments Keep Falling Short
None of the medications gave Jeremiah lasting relief. Doctors call this treatment-resistant depression, generally defined as major depressive disorder that does not improve after at least two full attempts with different antidepressants at proper doses. It is not rare, and it is not a sign a patient is doing something wrong. It simply means the brain is not responding the way doctors expect.
Jeremiah’s doctor eventually turned to SPRAVATO, the brand name for esketamine nasal spray. The Food and Drug Administration approved it specifically for adults with treatment-resistant depression, used alone or alongside an oral antidepressant. It works differently than older pills, acting fast on brain chemistry instead of taking weeks to build up.
A Treatment Built On Partnership, Not Just A Prescription
Jeremiah did not go through treatment alone. His wife stood beside him through appointments and hard days, and his doctor stayed closely involved in adjusting his care. That kind of support matters. Medication can open a door, but people still need someone walking the recovery path with them to actually get better.
Real-world studies back up what Jeremiah experienced. One multicenter study found depression symptoms and daily functioning kept improving over six months of esketamine treatment, with the biggest gains in how patients handled everyday life building steadily over time. Another large analysis found patients were about five times more likely to reach remission compared with standard care alone.
What The Science Says Beyond One Man’s Story
A major study called SUSTAIN-3 tracked hundreds of patients and found close to 37 percent reached what researchers call functional remission during longer-term treatment. That is real progress for a group of patients who had already failed other options. It is not everyone, but it is a meaningful share of people getting their lives back.
Not every review paints a simple picture. A Cochrane analysis noted that esketamine’s effectiveness for directly preventing suicide or reducing suicidal thoughts has not been firmly proven through study data. That distinction matters for patients and families weighing treatment choices, even as the drug’s approval for treatment-resistant depression itself rests on separate clinical trial evidence.
A Story Worth Taking Seriously
Jeremiah’s recovery reflects a pattern doctors increasingly recognize. Some patients with stubborn, treatment-resistant depression genuinely turn a corner with esketamine therapy, especially when paired with steady support from a spouse and a doctor committed to the process. For families watching a loved one struggle the way Jeremiah once did, his story offers something rare: a concrete, documented path forward, backed by both personal testimony and a growing body of clinical research.
Sources:
menshealth.com, spravato.com, accessdata.fda.gov, cambridge.org, link.springer.com
